Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus

REFERENCES

• Cieglik P, flrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Auto-immunity. 2012;45:119–28.
   Google Scholar
• Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28:1–13.
   PubMed Web of Science ®Google Scholar
• Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011;343: 237–49.
   Google Scholar
• Luchetti MM, Piccinini G, Mantovani A, Pen G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:196–202.
   PubMed Web of Science ®Google Scholar
• Dagna L, Salvo F, Tiraboschi M, Bozzolo EP, Franchini S, Doglioni C, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011;155:425–33.
   PubMed Web of Science ®Google Scholar
• Fazzini F, Pen i G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001;44: 2841–50.
   Google Scholar
• Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–6.
   PubMed Web of Science ®Google Scholar
• Muller B, Pen i G, Doni A, Tom V, Landmann R, Bottazi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404–7.
   PubMed Web of Science ®Google Scholar
• Pen G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypic long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102: 636–41.
   PubMedGoogle Scholar
• Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vase Biol. 2002;22: 10–4.
   PubMed Web of Science ®Google Scholar
• Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2307–15.
   Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, et al. Traditional Framingham risk scores fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331–7.
   Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–26.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of sys-temic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibariez D, Urowitz MB. Systemic lupus erythe-matosus disease activity index 2000. J Rheumatol. 2002;29: 288–91.
   Google Scholar
• Simmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a com-puterized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assesment Group (BILAG). Q J Med. 1988;69:927–37.
   Google Scholar
• Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8:632–7.
   PubMed Web of Science ®Google Scholar
• ACR AD HOC Committee on Neuropsychiatric Lupus Nomen-clature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
   Google Scholar
• Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. J Am Soc Nephrol 2004;15: 241–50 (Erratum in: J Am Soc Nephrol. 2004;15: 835–6).
   Google Scholar
• Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Sagara M, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vase Biol. 2007;27:161–7.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47: 471–7.
   PubMed Web of Science ®Google Scholar
• Hollan I, Bottazzi B, Cuccovillo I, Forre OT, Mikkelsen K, Saatvedt K, et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheu-matic disease. Arthritis Care Res. 2010;62:378–85.
   PubMed Web of Science ®Google Scholar
• Kim J, Koh JK, Lee EY, Park JA, Kim HA, Lee EB, et al. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (5TREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin Exp Rheum. 2009;27:773–8.
   PubMed Web of Science ®Google Scholar
• Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Tafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus. 2011;20:1494–500.
   Google Scholar
• Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol. 2008;26:814–9.
   Google Scholar
• Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19: 685–708.
   Google Scholar
• Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:2350–7.
   PubMed Web of Science ®Google Scholar
• Hanly JG, Urowitz MB, Su L, Gordon C, Clarke A, Bernatsky S, et al. Antoantibodies as biomarkers for the prediction of neuro-psychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1726–32.
   PubMed Web of Science ®Google Scholar
• Dom A, Mantovani G, Porta C, Tuckermann J, Reichardt HM, Kleiman A, et al. Cell-specific regulation of PTX3 by glucocor-ticoid hormones in hematopoietic and nonhematopoietic cells. J Biol Chem. 2008;283:29983–92.
   PubMed Web of Science ®Google Scholar